{"id":"NCT01400139","sponsor":"Purdue Pharma LP","briefTitle":"Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.","officialTitle":"An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-08","completion":"2013-10","firstPosted":"2011-07-22","resultsPosted":"2014-12-04","lastUpdate":"2020-03-10"},"enrollment":922,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Nonmalignant and Nonneuropathic Pain"],"interventions":[{"type":"DRUG","name":"Hydrocodone bitartrate q24h film-coated tablets","otherNames":["Hysingla ER"]}],"arms":[{"label":"Hydrocodone bitartrate","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.","primaryOutcome":{"measure":"The Number of Participants With Adverse Events as a Measure of Safety","timeFrame":"Up to 84 weeks","effectByArm":[{"arm":"HYD Core Study","deltaMin":80,"sd":null},{"arm":"HYD Extension Period","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":98,"countries":["United States"]},"refs":{"pmids":["26312961","28072811","26749219","26681111"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":922},"commonTop":["Nausea","Constipation","Dizziness","Somnolence","Vomiting"]}}